NCT04060017
Early Treatment of Language Impairment in Young Children With Autism Spectrum Disorder With Leucovorin Calcium
At risk: Primary completion moved 6 months later.
See at-risk trials from Southwest Autism Research & Resource Center
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 12 versions: 12 with changes below. See every version on ClinicalTrials.gov ↗
Notable Primary and study completion pushed from Jul 31, 2026 to Jan 31, 2027 Show 4 more changesShow less
- Eligibility criteria expanded, about 23 words
- Secondary endpoints: details revised at 13 of 13 entries
- Site details revised at 1 of 2 sites
- Publications: details revised at 5 of 5 entries
- Notable Primary and study completion dates pushed to Jul 31, 2026
- Trial status: Recruiting to Active, Not Recruiting
- Site details revised at 2 of 2 sites
- Notable Primary completion date: Jan 2025 to Dec 2025
- Study completion date: Jan 2025 to Jun 2026
- Minor Site contacts updated at 2 of 2 sitesv9
Notable Lead sponsor: Rossignol Medical Center to Southwest Autism Research & Resource Centerv8 Show 4 more changesShow less
- Trial status: Active, Not Recruiting to Recruiting
- Secondary endpoints: 14 to 13
- Site details revised at 2 of 2 sites
- Collaborators: 3 to 2
Show 6 earlier versionsHide 6 earlier versions
- Notable Primary and study completion dates: Jan 2023 to Jan 2025v7
- Notable Trial status: Suspended to Active, Not Recruiting
- Study sites revised (2)
Stopped Trial status: Recruiting to Suspended Sponsor's reason: Pending New IRB Approvalv5 Show 6 more changesShow less
- Lead sponsor: Phoenix Children's Hospital to Rossignol Medical Center
- Eligibility criteria expanded, about 23 words
- Primary and study completion dates: Dec 2022 to Jan 2023
- Secondary endpoints revised (14)
- Study sites revised (2)
- Collaborators: 4 to 3
Notable Trial status: Not Yet Recruiting to Recruitingv4 Show 4 more changesShow less
- Eligibility criteria expanded, about 103 words
- Start date changed from estimate of Oct 1, 2020 to Sep 22, 2020
- Secondary endpoints: 13 to 14
- Site details revised at 2 of 2 sites
- Notable Primary and study completion dates: Dec 2021 to Dec 2022
- Start date: May 2020 to Oct 1, 2020
- Notable Start date: Dec 2019 to May 2020v2
- Study First Submitted
- Stopped: terminated, suspended or withdrawn
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Secondary (12)
Show 7 moreShow less
Arms and interventions
The liquid form of leucovorin calcium will be dosed by weight, with a target dose of 1mg/kg/day, divided into two daily doses. This product may be taken alone or mixed with liquid. Participants randomized to this arm will receive active treatment for both 12-week phases of the study.
The placebo will mimic the experimental treatment in flavor, odor, packaging, and dosing instructions. Participants randomized to this arm will receive placebo for the first 12 weeks of the study, then active treatment for the remaining 12 weeks.
Drugs: Levoleucovorin Calcium
Other: Placebo
Sites
2 sites in 1 country